Introduction {#s1}
============

Over the past decades, there has been an increasing understanding of the disease process in human carcinoma. It is now well established that carcinoma can be initiated by DNA damage from UV exposure, ionizing radiation, environmental chemical agents, and byproducts of cell metabolism. Normally, when DNA damage occurs, DNA repair systems recognize the DNA lesions, excise them, and restore the DNA to maintain genome stability and integrity \[[@B1]\]. However, if genetic alterations occur in genes encoding DNA repair proteins, the DNA repair process may be impaired, potentially contributing to an increased risk for developing cancers.

The O^6^-methylguanine-DNA methyltransferase (MGMT) is one of the most important proteins in the DNA repair process. It is a 207 amino acid zinc-bound protein which is encoded by MGMT gene located on chromosome 10 at 10q26 and spans approximately 300kb \[[@B2]\]. It has been shown that MGMT has basic methyl-transferring activity \[[@B3]\] and plays a central role in the cellular defense against alkylating agents within the human DNA direct reversal repair pathway.

Also known as O^6^-alkylguanine--DNA alkyltransferase (ATase, AGT, or AGAT), MGMT protein can directly remove alkyl or methyl adducts from the *O* ^*6*^position of guanine to an internal cysteine residue at codon 145 of the protein \[[@B4]\]. By which, it protects cells against potential DNA alkylation damage from endogenous and exogenous alkylating species such as cigarette consumption, environmental contaminants, and diet \[[@B5]\]. Additionally, it seems that MGMT lacks the ability to dealkylate itself. MGMT therefore can take part only in a single reaction, in which it is irreversibly inactivated \[[@B6]\]. Hence, the reaction should be stoichiometric rather than catalytic. The MGMT expression shows significant variation not only among different body tissues \[[@B7]\], but also among individuals in the same specific tissue \[[@B8]\]. Though the causes of the inter-individual differences in MGMT protein expression levels remain unclear to date, functional polymorphisms in the MGMT gene may have the potential to affect DNA repair capacity. Because of its important role in human DNA direct reversal repair pathway, MGMT has attracted significant attention as a candidate susceptibility gene for cancer.

A large number of molecular epidemiology studies have been carried out to assess the roles of the MGMT polymorphisms in various types of cancer, including lung cancer, head and neck cancer, and colorectal cancer \[[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21]\]. The MGMTLeu84Phe substitution is the most widely studied polymorphism in MGMT due to a (C-\>T) transition at nt.262 (MGMT Leu84Phe, rs12917). However, numerous studies on the association of the MGMT Leu84Phe polymorphism with cancer risk have yielded inconsistent results and even partially contradictory conclusions. Several factors may contribute to the discrepancies among different studies. The differences of tumor sites, ethnicities or sample size may all cause the bias of the result of each individual study.

Since single studies may have been underpowered in clarifying the associations of MGMT polymorphisms with cancer susceptibility, to address the controversy among literatures, in the present study we conducted an evidence-based quantitative meta-analysis of the association between the *MGMT* Leu84Phe polymorphism and susceptibility to cancer.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2.1}
--------------------------------------------------

To identify all studies that explored the association of MGMT Leu84Phe polymorphism with cancer risk, we carried out a computerized literature search of the PubMed database (up to July 20, 2012), using the following key words: 'MGMT,' 'polymorphism,' and 'cancer,' without any restriction on language or publication year. The searched papers were read and assessed for their appropriateness of including. All references cited in the articles were also read to identify relevant publications. Eligible studies should meet two criteria: (1) case-control studies; and (2) genotype frequencies in both cancer cases and controls were available. Exclusion criteria were as follows: (a) not relevant to MGMT Leu84Phe polymorphism; (b) not case-control study; (c) control population included malignant tumor cases; and (d) article was a review or duplication of previous publication.

Data extraction {#s2.2}
---------------

The data was extracted by two investigators (Jun Liu and Fei Chen) from each article independently. Discrepancies were not solved until consensus was reached on every item. From each study, the following data were collected: author's name, year of publication, country of origin, racial descent, cancer type, source of the control population, genotyping methods, matched factors as well as adjusted factors, number of cases and controls, genotype frequencies for cases and controls, characteristics of cancer cases, and controls. If data of subpopulation from different ethnicities was available in one paper, we took each subpopulation as an individual study.

Statistical analysis {#s2.3}
--------------------

Hardy-Weinberg equilibrium (HWE) for each study was assessed using goodness-of-fit test (x^2^ of Fisher's exact test) only in control groups \[[@B22]\]. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of association between MGMTLeu84Phe polymorphism and cancer susceptibility. In the overall and subgroup meta-analysis, we evaluated the associations of genetic variants with cancer risk in homozygous genetic contrast (TT vs. CC), dominant geneticmodel (CT+TT vs. CC), recessive genetic model (TT vs. CT+CC) and T allele vs C allele. The significance of the pooled OR was assessed by the Z-test (*P*\<0.05 shows a significant association). In addition to overall meta-analysis, stratified analysis on ethnicity (Asians, Caucasians, and the other ethnicities group) and tumor site was also performed A x^2^-based Q-test was carried out to assess the heterogeneity of the ORs \[[@B23]\]. If the result of heterogeneity test was *P*\>0.1, ORs were pooled according to the fixed-effects model (Mantel-Haenszel model). Otherwise, the random-effects model (DerSimonian and Laird model) was applied \[[@B24]\]. The Egger regression test and Begg-Mazumdar test were utilized to measure the potential publication bias \[[@B25]\]. All statistical tests were conducted with the software STATA v.10.0 (Stata Corporation, College Station, TX, USA) using two-side *P* values.

Results {#s3}
=======

Characteristics of studies {#s3.1}
--------------------------

The preliminary literature search yielded 46 articles that explored the association of MGMT polymorphisms with the susceptibility to different cancers. However, six articles \[[@B26],[@B27],[@B28],[@B29],[@B30],[@B31]\] irrelevant to MGMT Leu84Phe polymorphism and four articles \[[@B32],[@B33],[@B34],[@B35]\] without detailed MGMT Leu84Phe genotypes data were excluded. In addition, three articles \[[@B10],[@B36],[@B37]\] were included by literature reading and manual searching. Therefore, 39 articles \[[@B9]-[@B21], [@B36]-[@B61]\] were identified and included in the final meta-analysis ([Figure **1**](#pone-0075367-g001){ref-type="fig"}). Five papers \[[@B14]\], \[[@B18]\] \[[@B56]\], \[[@B59]\], and \[[@B61]\] presented data including more than one racial populations and each subgroup in these studies was taken as a separate study. Therefore, a total of 44 studies from 39 papers (18938 cancer patients and 28796 controls) were included. All of the cases were confirmed by histological or pathological examination. A classic polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was adopted only in 7 of 44 studies and some other genotyping methods were also used widely, such as Taqman, sequencing and Illumina SNP genotyping BeadLab platform. All the genotyping methods are valid for the present meta-analysis. All studies stated that the gender status and the age range were matched between case and control population. The characteristics of included studies are listed in [Table **1**](#pone-0075367-t001){ref-type="table"}. All studies were case-control studies or nested case-control studies within prospective cohort studies, including 9 upper aerodigestive tract squamous cell carcinoma (UADT SCC) studies, 7 colorectal cancer studies, 5 lung cancer studies, 4 brain cancer studies, 3 prostate studies and 13 studies on "other cancers". There were 15 studies of Caucasian ethnicity, 13 studies of Asian ethnicity, and 16 studies of "mixed ethnicities" (including studies of American, Australian, Black and unspecified population, which cannot be categorized as a unique group since it is mixed). The detailed MGMT Leu84Phe genotype distributions and allele frequencies for cancer cases and controls were presented in [Table **2**](#pone-0075367-t002){ref-type="table"}. The equilibrium of genotypes in the controls was consistent with HWE in all but five studies \[[@B9],[@B10],[@B17],[@B21],[@B45]\] (*P*=0.01, *P*=0.06, *P*=0.02, *P*\<0.01, *P*=0.04, respectively) ([Table **2**](#pone-0075367-t002){ref-type="table"}).

![Studies identified with criteria for inclusion and exclusion.](pone.0075367.g001){#pone-0075367-g001}

10.1371/journal.pone.0075367.t001

###### Characteristics of studies included in the meta-analysis.

  First author and published year   Country        Cancer                      Racial descent       Source of controls    No. of cases/controls   Matching
  --------------------------------- -------------- --------------------------- -------------------- --------------------- ----------------------- ------------------------
  Inoue (2003)                      Japan          Brain tumors                Asian                Population            73/224                  Age
  Krzensniak (2004)                 Poland         Lung cancer                 Caucasian            Population            96/96                   Age,Sex,Smoking
  Bigler (2005)                     America        Colorectal cancer           American             Hospital              517/615                 None
  Huang (2005)                      Poland         Gastric cancer              Caucasian            Population            280/387                 Age,Sex
  Huang (2005) 1                    America        Head and neck SCC           Caucasian            Population/hospital   400/665                 Age,Sex, Race
  Huang (2005) 2                    America        Head and neck SCC           Non-white American   Population/hospital   114/89                  Age,Sex, Race
  Li (2005)                         China          Bladder cancer              Asian                Population            167/204                 Age,Sex, Smoking
  Ritchey (2005)                    China          Prostate cancer             Asian                Population            161/246                 Age
  Shen (2005)                       America        Breast cancer               American             Population            1064/1107               Age
  Chae (2006)                       Korea          Lung cancer                 Asian                Hospital              432/432                 Age,Sex
  Han (2006)                        America        Endometrial cancer          Caucasian            Population            434/1085                Age
  Han (2006)                        America        Breast cancer               Caucasian            Population            1276/1714               Age
  Jiao (2006)                       America        Pancreatic cancer           American             Hospital              370/340                 Age,Sex, Race
  Kietthubthew (2006)               Thailand       Oral SCC                    Asian                Population            106/164                 Age,Sex
  Moreno (2006)                     Spain          Colorectal cancer           Caucasian            Hospital              272/299                 None
  Tranah (2006) 1                   America        Colorectal cancer           American (PHS)^c^    Hospital              186/2137                Age,Smoking
  Tranah (2006) 2                   America        Colorectal cancer           American (NHS)^d^    Hospital              257/429                 Age
  Wang (2006)                       America        Lung cancer                 Caucasian            Hospital              1121/1163               Age,Sex, Race,Smoking,
  Zienolddiny (2006)                Norway         Lung cancer                 Caucasian            Population            304/363                 Age,Smoking
  Felini (2007)                     America        Gliomas                     American             Population            379/459                 Age,Sex, Race
  Hall (2007)                       Europe^a^      UADT SCC                    Caucasian            Hospital              803/1062                Age,Sex, Residence
  Hu (2007)                         China          Lung cancer                 Asian                Hospital              500/517                 Age,Sex, residence
  Huang (2007)                      China          Cervical cancer             Asian                Hospital              539/800                 Age,Residence
  Shen (2007)                       Australia      Non-Hodgkin's lymphoma      Australian           Population            555/495                 Age,Sex, Residence
  Stern (2007)                      Singapore      Colorectal cancer           Asian                Population            292/1166                None
  Doecke (2008)                     Australia      Esophageal adenocarcinoma   Australian           Population            566/1337                Age,Residence
  Zhang (2008)                      China          Biliary tract cancer        Asian                Population            406/782                 None
  Hazra (2008)                      America        Colorectal cancer           American             Population            358/357                 Age
  kbari (2009)                      Iran           Esophageal SCC              Asian                Hospital              196/250                 None
  Gu (2009)                         America        Melanoma                    American             Population            214/212                 Age, Race
  Khatami (2009)                    Iran           Colorectal cancer           Asian                Hospital              200/201                 Age,Sex
  Liu (2009)                        America        Glioma                      American             Population            369/363                 Age,Sex, Race
  McKean-Cowdin (2009)              America        Glioblastoma                Caucasian            Population/hospital   998/1968                Age,Sex, Race
  Yang (2009)                       China          Non-Hodgkin's lymphoma      Asian                Hospital              48/352                  None
  Agalliu (2010) 1                  America        Prostate cancer             Caucasian            Population            1250/1237               Age
  Agalliu (2010) 2                  America        Prostate cancer             African-American     Population            147/81                  Age
  Huang (2010)                      America        Oral SCC                    Asian                Hospital              176/110                 None
  Palli (2010)                      China          Gastric cancer              Caucasian            Population            291/537                 None
  Zhang (2010)                      Italy          Head and neck SCC           Caucasian            Hospital              721/1234                Age,Sex
  Bye (2011) 1                      America        Esophageal SCC              Black                Population            346/469                 Age,Sex, Race
  Bye (2011) 2                      South Africa   Esophageal SCC              Mixed ethnicities    Population            196/423                 Age,Sex, Race
  Loh (2011)                        South Africa   Cancers                     Caucasian            Population            188/1120                None
  O'Mara (2011) 1                   UK^b^          Endometrial cancer          Australian           Population            1173/1099               Age,Residence
  O'Mara (2011) 2                   Australia      Endometrial cancer          Caucasian            Population            397/406                 Age

SCC- squamous cell carcinoma；UADT SCC - Upper Aerodigestive Tract Squamous Cell Carcinoma

a: Include 5 central and eastern European countries

b: Indlude Norfolk, East Anglia and United Kingdom

c: PHS- Physicians' Health Study d: NHS-Nurses' Health Study

10.1371/journal.pone.0075367.t002

###### Distribution of MGMT Leu84Phe genotypes and allelic frequency.

  Study (year)           Distribution of MGMT Leu85Phe genotypes         Frequency of MGMT Leu85Phe alleles   HWE *P* value                                                     
  ---------------------- ----------------------------------------- ----- ------------------------------------ --------------- ------ ----- ---- -- ------ ----- -- ------ ----- ----------
  Inoue (2003)           55                                        18    0                                                    160    55    9       128    18       375    73    0.13
  Krzensniak (2004)      67                                        23    6                                                    74     17    5       157    35       165    27    **0.01**
  Bigler (2005)          403                                       108   6                                                    466    136   13      914    120      1068   162   0.41
  Huang (2005)           190                                       82    8                                                    279    99    9       462    98       657    117   0.95
  Huang (2005) a         315                                       80    5                                                    468    179   18      710    90       1115   215   0.86
  Huang (2005) b         71                                        37    6                                                    61     25    3       179    49       147    31    0.82
  Li (2005)              132                                       34    1                                                    173    28    3       298    36       374    34    0.15
  Ritchey (2005)         123                                       36    2                                                    213    32    1       282    40       458    34    0.86
  Shen (2005)            778                                       265   21                                                   824    263   20      1821   307      1911   303   0.85
  Chae (2006)            344                                       84    4                                                    341    81    10      772    92       763    101   **0.06**
  Han (2006)             344                                       82    8                                                    822    242   21      770    98       1886   284   0.52
  Han (2006)             964                                       279   33                                                   1306   382   26      2207   345      2994   434   0.75
  Jiao (2006)            264                                       101   5                                                    257    82    1       629    111      596    84    **0.04**
  Kietthubthew (2006)    84                                        21    1                                                    130    33    1       189    23       293    35    0.48
  Moreno (2006)          213                                       47    12                                                   225    63    11      473    71       513    85    **0.02**
  Tranah (2006) a        147                                       33    6                                                    1634   471   32      327    45       3739   535   0.77
  Tranah (2006) b        204                                       47    6                                                    330    93    6       455    59       753    105   0.85
  Wang (2006)            832                                       259   30                                                   872    272   19      1923   319      2016   310   0.67
  Zienolddiny (2006)     189                                       102   13                                                   247    106   10      480    128      600    126   0.73
  Felini (2007)          289                                       84    6                                                    369    84    6       662    96       822    96    0.63
  Hall (2007)            574                                       198   31                                                   764    277   21      1346   260      1805   319   0.48
  Hu (2007)              418                                       77    5                                                    421    93    3       913    87       935    99    0.38
  Huang (2007)           372                                       156   11                                                   592    198   10      900    178      1382   218   0.15
  Shen (2007)            432                                       112   11                                                   373    110   12      976    134      856    134   0.26
  Stern (2007)           251                                       40    1                                                    959    194   13      542    42       2112   220   0.37
  Doecke (2008)          416                                       136   14                                                   1029   281   27      968    164      2339   335   0.13
  Zhang (2008)           352                                       53    1                                                    631    144   7       757    55       1406   158   0.70
  Hazra (2008)           271                                       72    15                                                   254    97    6       614    102      605    109   0.34
  Akbari (2009)          142                                       53    1                                                    185    63    2       337    55       433    67    0.17
  Gu (2009)              152                                       60    2                                                    168    43    1       364    64       379    45    0.32
  Khatami (2009)         40                                        160   0                                                    61     140   0       240    160      262    140   **0.00**
  Liu (2009)             299                                       62    8                                                    267    89    7       660    78       623    103   0.89
  McKean-Cowdin (2009)   774                                       204   20                                                   1480   453   35      1752   244      3413   523   0.96
  Yang (2009)            33                                        14    1                                                    289    58    5       80     16       636    68    0.29
  Agalliu (2010) a       949                                       269   32                                                   916    298   23      2167   333      2130   344   0.83
  Agalliu (2010) b       106                                       35    6                                                    60     20    1       247    47       140    22    0.64
  Huang (2010)           151                                       25    0                                                    89     21    0       327    25       199    21    0.27
  Palli (2010)           210                                       77    4                                                    395    131   11      497    85       921    153   0.97
  Zhang (2010)           563                                       151   7                                                    933    284   17      1277   165      2150   318   0.38
  Bye (2011) a           225                                       111   10                                                   300    155   14      561    131      755    183   0.26
  Bye (2011) b           120                                       65    11                                                   294    116   13      305    87       704    142   0.71
  Loh (2011)             146                                       37    5                                                    894    212   14      329    47       2000   240   0.72
  O'Mara (2011) a        889                                       261   23                                                   810    270   19      2039   307      1890   308   0.52
  O'Mara (2011) b        278                                       108   11                                                   296    103   7       664    130      695    117   0.57

Bold indicates statistically significant *P* value.

HWE Hardy--Weinberg equilibrium

Quantitative synthesis {#s3.2}
----------------------

In overall analysis, significant associations between the T allele and cancer risk were found under the recessive genetic model (*P*=0.001, OR=1.28, 95%CI 1.11-1.47) and TT versus CC comparison (*P*=0.001, OR=1.28, 95% CI 1.11-1.47). And, after we excluded those studies whose genotype equilibrium was not consistent with HWE, significant associations between the T allele and cancer susceptibility was also uncovered under the recessive genetic model (*P*\<0.001, OR=1.30, 95%CI 1.24-1.50) and TT versus CC comparison (*P*=0.001, OR=1.29, 95% CI 1.12-1.50). However, no significant association was found in the dominant genetic model (TT+TC versus CC) and T versus C comparison. These results were summarized in [Table **3**](#pone-0075367-t003){ref-type="table"}.

10.1371/journal.pone.0075367.t003

###### Summary ORs (95% CI) for MGMT Leu84Phe variant under different genetic models and tumor site.

  MGMT Leu85Phe              N^\#^   TT versus CC                      CT+TTversus CC                         TT versus CT+CC      T versus C                                                 
  -------------------------- ------- --------------------- ----------- ---------------- --------------------- ----------------- -- --------------------- ----------- -- --------------------- -------
  Total                      44      1.28 (1.11-1.47)      **0.001**                    1.01 (0.94-1.08)^b^   0.808                1.28 (1.11-1.47)      **0.001**      1.01 (0.96-1.08)^b^   0.504
  Total in HWE               39      1.29 (1.12-1.50)      **0.001**                    1.00 (0.93-1.07)^b^   0.890                1.30 (1.24-1.50)      **0.000**      1.01 (0.95-1.08)^b^   0.692
  UADT SCC                   9       1.24 (0.89-1.73)      0.197                        0.96 (0.82-1.13)^b^   0.626                1.25 (0.90-1.73)      0.189          0.98 (0.84-1.15)^b^   0.820
  Colorectal cancer          7       1.29 (0.85-1.95)      0.234                        0.89 (0.78-1.02)      0.091                1.35 (0.90-2.04)      0.152          0.94 (0.84-1.05)      0.267
  Colorectal cancer in HWE   5       1.25 (0.62-2.50)^b^   0.536                        0.84 (0.72-0.97)      **0.019**            1.30 (0.64-2.66)^b^   0.470          0.88 (0.77-1.01)      0.073
  Lung cancer                5       1.38 (0.92-2.06)      0.119                        1.05 (0.92-1.19)      0.485                1.34 (0.90-2.00)      0.147          1.06 (0.95-1.20)      0.298
  Lung cancer in HWE         3       1.67 (1.06-2.63)      **0.027**                    1.05 (0.91-1.21)      0.526                1.64 (1.04-2.58)      **0.032**      1.08 (0.95-1.23)      0.232
  Brain cancer               4       1.11 (0.71-1.73)      0.664                        0.89 (0.68-1.16)^b^   0.390                1.42 (0.73-1.79)      0.562          0.90 (0.72-1.13)^b^   0.375
  Prostate cancer            3       1.48 (0.88-2.48)      0.136                        1.22 (0.74-2.00)^b^   0.445                1.51 (0.91-2.53)      0.113          1.25 (0.81-1.94)^b^   0.321
  Endomtrial cancer          3       1.14 (0.74-1.77)      0.560                        0.92 (0.80-1.06)      0.240                1.64 (0.75-1.80)      0.495          0.95 (0.84-1.07)      0.394
  Other cancers              13      1.17 (0.88-1.54)      0.281                        1.10 (0.97-1.26)^b^   0.147                1.14 (0.87-1.51)      0.350          1.09 (0.97-1.23)^b^   0.152
  Other cancers in HWE       12      1.14 (0.86-1.51)      0.368                        1.09 (0.95-1.26)~b~   0.216                1.12 (0.84-1.47)      0.446          1.08 (0.95-1.22)^b^   0.236

Bold indicates statistically significant *P* value

All summary ORs were calculated using fixed-effects models, unless stated otherwise

\# Number of studies

b Random-effect models

HWE − Hardy Weinberg Equilibrium

When the subgroup analyses were carried out according to tumor site, the MGMT T allele was associated with a significant increase in risk of lung cancer (TT Versus CC, P=0.027, OR =1.67, 95% CI 1.06-2.63; recessive genetic model, *P*=0.32, OR=1.64, 95% CI 1.04-2.58). By contrast, a significant protective effect was found for colorectal cancer under the dominant genetic model (*P*=0.019, OR=0.84, 95% CI 0.72-0.97). However, no significant association was found in other tumor sites subgroups under all genetic models. These results are also listed in [Table **3**](#pone-0075367-t003){ref-type="table"}.

In most of the available studies, there was no difference of MGMT Leu84Phe genotype/allele distribution among different ethnicities. We also performed stratified analysis by ethnicity (Caucasians, Asians, and mixed ethnicities), and by ethnicity and tumor site together ([Table **4**](#pone-0075367-t004){ref-type="table"}). In subgroup meta-analysis by ethnicity, significant associations between TT and recessive genetic model and total cancer risk were found in the Caucasian population (TT versus CC, P=0.004, OR =1.32, 95% CI 1.10-1.61; recessive genetic model, *P*=0.002, OR=1.34, 95% CI 1.11-1.62) and in the mixed ethnicities population (TT versus CC, P=0.041, OR =1.27, 95% CI 1.01-1.60; recessive genetic model, *P*=0.037, OR=1.28, 95% CI 1.02-1.61). And, when those studies without consistency with HWE were excluded, a significant association was still found for the Caucasian population (TT versus CC, P=0.014, OR =1.29, 95% CI 1.05-1.59; recessive genetic model, *P*=0.009, OR=1.31, 95% CI 1.07-1.61). However, in the Asian subgroup and the mixed ethnicities subgroup, no significant association was observed for any genetic model. In the analysis stratified by ethnicity and tumor site ([Table **4**](#pone-0075367-t004){ref-type="table"}), we found an increased risk only in the Caucasian subgroup for lung cancer (TT versus CC, P=0.035, OR =1.62, 95% CI 1.04-2.53; recessive genetic model, *P*=0.048, OR=1.57, 95% CI 1.01-2.45).

10.1371/journal.pone.0075367.t004

###### Summary ORs (95% CI) for MGMT Leu84Phe variant categorized by ethnicity and ethnicity / tumor site under different genetic models.

  MGMT Leu85Phe              N^\#^   TT versus CC                      TT+TC versus CC                         TT versus TC + CC      T versus C                                                 
  -------------------------- ------- --------------------- ----------- ----------------- --------------------- ------------------- -- --------------------- ----------- -- --------------------- -------
  Caucasian                  15      1.32 (1.10-1.61)      **0.004**                     0.98 (0.90-1.06)^b^   0.560                  1.34 (1.11-1.62)      **0.002**      1.00 (0.93-1.09)^b^   0.923
  Caucasian in HWE           13      1.29 (1.05-1.59)      **0.014**                     0.96 (0.88-1.06)^b^   0.407                  1.31 (1.07-1.61)      **0.009**      0.99 (0.91-1.08)^b^   0.827
  Asian                      13      0.97 (0.58-1.61)      0.898                         1.07 (0.88-1.31)^b^   0.485                  0.94 (0.57-1.56)      0.805          1.03 (0.86-1.22)^b^   0.779
  Asian in HWE               11      1.19 (0.68-2.09)      0.546                         1.04 (0.83-1.30)^b^   0.724                  1.15 (0.65-2.01)      0.633          1.02 (0.83-1.26)^b^   0.861
  Mixed ethnicities          16      1.27 (1.01-1.60)      **0.041**                     1.01 (0.91-1.13)^b^   0.813                  1.28 (1.02-1.61)      **0.037**      1.04 (0.95-1.13)^b^   0.457
  Mixed ethnicities in HWE   15      1.25 (0.99-1.58)      0.057                         1.00 (0.90-1.12)^b^   0.997                  1.26 (1.00-1.58)      0.052          1.08 (0.95-1.22)^b^   0.236
  **Caucasian**                                                                                                                                                                                  
  Lung cancer                3       1.62 (1.04-2.53)      **0.035**                     1.12 (0.96-1.31)      0.159                  1.57 (1.01-2.45)      **0.048**      1.14 (0.99-1.31)      0.061
  UADT SCC                   3       0.88 (0.33-2.33)^b^   0.794                         0.85 (0.66-1.08)^b^   0.182                  0.92 (0.36-2.35)^b^   0.865          0.87 (0.66-1.14)^b^   0.312
  **Asian**                                                                                                                                                                                      
  UADT SCC                   3       0.94(01.15-5.84)      0.950                         0.96(0.7101.30)       0.800                  0.93 (0.15-5.76)      0.939          0.97 (0.73-1.28)      0.802
  **Mixed ethnicities**                                                                                                                                                                          
  Colorectal cancer          4       1.46 (0.89-2.38)      0.134                         0.85 (0.72-1.01)      0.059                  1.53 (0.94-2.50)      0.088          0.91 (0.79-1.06)      0.220

Bold indicates statistically significant *P* value

All summary ORs were calculated using fixed-effects models, unless stated otherwise

\# Number of studies

b Random-effect models

UADT SCC − Upper Aerodigestive Tract Squamous Cell CarcinomaHWE − Hardy Weinberg Equilibrium

As shown in [Table **3** and Table **4**](#pone-0075367-t003){ref-type="table"}, heterogeneity widely existed in the present meta-analysis under the dominant genetic mode and T versus C comparison but not under the homozygous comparison and recessive genetic model.

Publication bias {#s3.3}
----------------

Begg's funnel plot and Egger's test were utilized to evaluate the publication bias of the literature. As shown in [Figure **2**](#pone-0075367-g002){ref-type="fig"}, the contour-enhanced funnel plot for publication bias did not reveal any evidence of obvious asymmetry in allele contrast (T allele versus C allele), and, as expected, the Egger's test did not provide any obvious evidence for bias (*t*=0.12, *P*=0.902).

![Begg's funnel plot analysis to detect publication bias (MGMT : Leu84Phe T allele versus C allele).\
Each point represents a separate study for the indicated association. Logor represents natural logarithm of OR. Horizontal line represents the mean effects size.](pone.0075367.g002){#pone-0075367-g002}

Discussion {#s4}
==========

This meta-analysis including a total of 18938 cancer patients and 28796 controls from 44 independent genetic studies implies that MGMT Leu84Phe polymorphism might contribute to the susceptibility of certain cancers

Although the global analysis indicated that the T variant allele might increase the risk of cancer, the subgroup meta-analysis showed significant association at only two tumor sites (colorectal cancer and lung cancer) and two ethnicity subgroups (Caucasian subgroup and mixed ethnicities subgroup). This phenomenon suggests that the MGMT Leu84Phe polymorphism may play differing roles in cancerogenesis at different sites or in different ethnicities because of variability in genetic backgrounds \[[@B62]\].

Since cancer is a complex disease, it is highly possible that any single genetic factor has only weak effects on an individual's phenotype. It has been reported that the interaction of different combinations of polymorphisms in the same gene or between and among different genes might together have a pronounced effect on cancer risk \[[@B63],[@B64],[@B65]\]. Studies by Li et al. \[[@B66],[@B67]\] have shown that MGMT is a transcriptional suppressor of ER-dependent signaling upon repair of the O^6^-methylguanine lesion and that the Lue84 and Ile143 residues lie in close proximity to three conserved leucines of the LXXLL ER-interacting helix. Therefore, it is possible that the ER-dependent signalling could be differentially mediated by the variant 84Phe and 143Val residues. Some studies \[[@B9],[@B10],[@B13],[@B40],[@B42],[@B48],[@B49],[@B54]\] have tried to investigate the combined effects of Lue84Phe, Ile143Val, and other polymorphisms in MGMT on cancer risk. Because the available data were not compatible, we could not evaluate the combined effects of MGMT Leu84Phe and Ile143Val on cancer susceptibility in our meta-analysis.

It is well established that genetic factors may play an important role in the development of tumors. However, there is no doubt that environmental factors such as alcohol consumption, cigarette use, and aging also participate in tumorigenesis. Several studies \[[@B11],[@B39],[@B42]\] reported that heavy cigarette smoking could aggravate the effects of MGMT variants on cancer risk. However, Chae et al. \[[@B10]\] did not find the same results. Li et al. \[[@B40]\] found that both drinking and smoking enhance genetic variants' effects on bladder cancer risk. It should be noted that alcohol consumption and cigarette use may play different roles at different tumor sites because of the different levels of alkylating agents and different tissue exposure concentrations. Unfortunately, owing to a lack of studies restricted to populations only exposed to alkylating agents, we could not obtain enough original data to further estimate the effects of the gene-environment interactions on cancer susceptibility.

We note several limitations in the present study. First, there was wide heterogeneity due to the nature of our meta-analysis, and the results should be interpreted with caution. Second, our results were based on unadjusted information, and the lack of original data limited estimation of the effect of confounding factors on cancer risk. Notably, confounding factors such as sex, age, alcohol drinking, smoking, and socioeconomic status may alter the association of genetic variants with cancer susceptibility. Third, the number of eligible studies in the subgroup analysis was limited. Subsequently, some subgroup meta-analysis might not have enough statistical power to accurately evaluate the association between the MGMT Leu84Phe polymorphism and cancer risk. More importantly, haplotype analysis has been regarded as a much better approach in genetic association research. However, since more detailed individual information on genotypes of the other polymorphisms of MGMT was unavailable, we were not able to conduct linkage disequilibrium and haplotype analysis in this study.

In conclusion, we observed several significant associations of the MGMT Leu84Phe polymorphism with cancer susceptibility. MGMT Leu84Phe variants may increase lung cancer risk, especially in Caucasians, but reduce colorectal cancer risk, indicating some differences among different tumor sites. In addition, MGMT Leu84Phe variants may increase cancer risk in Caucasians and in the mixed ethnicities group, which suggests an appreciable difference among different ethnic populations. Further well-designed study with greater sample size will be helpful in clarifying the haplotypes, gene--gene and gene--environment interactions on MGMT polymorphisms and tissue-specific cancer risk in ethnicity specific populations, and further mechanistic studies are warranted to elucidate the exact functional roles of MGMT variants.
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